NBRV Nabriva Therapeutics plc

Price (delayed)

$1.18

Market cap

$586.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$533.47M

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for ...

Highlights
Nabriva Therapeutics's revenue has surged by 115% QoQ and by 70% YoY
NBRV's gross profit has soared by 76% QoQ and by 29% YoY
The quick ratio is down by 22% year-on-year but it is up by 17% since the previous quarter
The gross margin is down by 24% year-on-year and by 18% since the previous quarter
The company's debt rose by 5% YoY

Key stats

What are the main financial stats of NBRV
Market
Shares outstanding
497.39M
Market cap
$586.92M
Enterprise value
$533.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.04
Price to sales (P/S)
32.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.73
Earnings
Revenue
$14.52M
EBIT
-$54.93M
EBITDA
-$54.02M
Free cash flow
-$66.21M
Per share
EPS
-$0.27
Free cash flow per share
-$0.16
Book value per share
$0.2
Revenue per share
$0.04
TBVPS
$0.24
Balance sheet
Total assets
$95.41M
Total liabilities
$26.21M
Debt
$7.87M
Equity
$69.2M
Working capital
$75.41M
Liquidity
Debt to equity
0.11
Current ratio
4.93
Quick ratio
3.8
Net debt/EBITDA
0.99
Margins
EBITDA margin
-372%
Gross margin
72%
Net margin
-389.2%
Operating margin
-387.8%
Efficiency
Return on assets
-78%
Return on equity
-116.8%
Return on invested capital
-403.5%
Return on capital employed
-72.1%
Return on sales
-378.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBRV stock price

How has the Nabriva Therapeutics stock price performed over time
Intraday
1.72%
1 week
6.31%
1 month
11.32%
1 year
100%
YTD
-51.24%
QTD
-0.84%

Financial performance

How have Nabriva Therapeutics's revenue and profit performed over time
Revenue
$14.52M
Gross profit
$10.45M
Operating income
-$56.32M
Net income
-$56.52M
Gross margin
72%
Net margin
-389.2%
Nabriva Therapeutics's revenue has surged by 115% QoQ and by 70% YoY
NBRV's gross profit has soared by 76% QoQ and by 29% YoY
The company's net margin has surged by 58% YoY and by 56% QoQ
The operating margin has soared by 56% since the previous quarter and by 55% year-on-year

Growth

What is Nabriva Therapeutics's growth rate over time

Valuation

What is Nabriva Therapeutics stock price valuation
P/E
N/A
P/B
6.04
P/S
32.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.73
Nabriva Therapeutics's EPS has soared by 70% YoY and by 29% from the previous quarter
NBRV's P/B is 68% below its 5-year quarterly average of 18.6 and 48% below its last 4 quarters average of 11.7
NBRV's equity has soared by 56% YoY and by 26% from the previous quarter
Nabriva Therapeutics's revenue has surged by 115% QoQ and by 70% YoY
The P/S is 85% below the 5-year quarterly average of 218.9 and 69% below the last 4 quarters average of 107.6

Efficiency

How efficient is Nabriva Therapeutics business performance
Nabriva Therapeutics's ROS has soared by 58% YoY and by 57% from the previous quarter
The ROE is up by 47% year-on-year and by 18% since the previous quarter
Nabriva Therapeutics's ROA has increased by 29% YoY and by 16% from the previous quarter
The return on invested capital rose by 26% since the previous quarter

Dividends

What is NBRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBRV.

Financial health

How did Nabriva Therapeutics financials performed over time
The company's total assets rose by 47% YoY and by 20% QoQ
The total liabilities is up by 27% year-on-year and by 7% since the previous quarter
The company's debt is 89% lower than its equity
NBRV's equity has soared by 56% YoY and by 26% from the previous quarter
The debt to equity is down by 35% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.